[go: up one dir, main page]

MX2022000030A - Proceso para la preparacion de un inhibidor de fosfodiesterasa (pde4). - Google Patents

Proceso para la preparacion de un inhibidor de fosfodiesterasa (pde4).

Info

Publication number
MX2022000030A
MX2022000030A MX2022000030A MX2022000030A MX2022000030A MX 2022000030 A MX2022000030 A MX 2022000030A MX 2022000030 A MX2022000030 A MX 2022000030A MX 2022000030 A MX2022000030 A MX 2022000030A MX 2022000030 A MX2022000030 A MX 2022000030A
Authority
MX
Mexico
Prior art keywords
preparation
pde4
phosphodiesterase
inhibitor
compound
Prior art date
Application number
MX2022000030A
Other languages
English (en)
Inventor
Alessandro Falchi
Emilio Lutero
Emanuele Ferrari
Fausto Pivetti
Rocco Bussolati
Edoardo Mariani
Orsola Vecchi
Erhard Bappert
Caterina Ventrici
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49385193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022000030(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MX2022000030A publication Critical patent/MX2022000030A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/59—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Proceso para la preparación de compuestos que poseen actividad inhibitoria de fosfodiesterasa (PDE4) de fórmula (I). La invención también se relaciona con el proceso para el aislamiento por cristalización del compuesto (I) y su uso para la preparación de composiciones farmacéuticas para inhalación en combinación con transportadores o vehículo adecuados. La presente invención también se relaciona con solvatos y formas cristalinas de un compuesto de fórmula (I). El producto sintetizado es adecuado para el uso en aplicaciones farmacéuticas por ejemplo en el tratamiento de enfermedades respiratorias.
MX2022000030A 2013-10-22 2016-04-14 Proceso para la preparacion de un inhibidor de fosfodiesterasa (pde4). MX2022000030A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13189784 2013-10-22

Publications (1)

Publication Number Publication Date
MX2022000030A true MX2022000030A (es) 2022-07-19

Family

ID=49385193

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2019014408A MX389002B (es) 2013-10-22 2014-10-17 Proceso para la preparación de un inhibidor de fosfodiesterasa (pde4).
MX2016004834A MX370104B (es) 2013-10-22 2014-10-17 Proceso para la preparacion de un inhibidor de fosfodiesterasa (pde4).
MX2022000030A MX2022000030A (es) 2013-10-22 2016-04-14 Proceso para la preparacion de un inhibidor de fosfodiesterasa (pde4).
MX2022000036A MX2022000036A (es) 2013-10-22 2016-04-14 Proceso para la preparacion de un inhibidor de fosfodiesterasa (pde4).

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2019014408A MX389002B (es) 2013-10-22 2014-10-17 Proceso para la preparación de un inhibidor de fosfodiesterasa (pde4).
MX2016004834A MX370104B (es) 2013-10-22 2014-10-17 Proceso para la preparacion de un inhibidor de fosfodiesterasa (pde4).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022000036A MX2022000036A (es) 2013-10-22 2016-04-14 Proceso para la preparacion de un inhibidor de fosfodiesterasa (pde4).

Country Status (29)

Country Link
US (7) US9434691B2 (es)
EP (5) EP3293176B1 (es)
JP (5) JP6458957B2 (es)
KR (3) KR102287598B1 (es)
CN (5) CN110256338A (es)
AR (4) AR098128A1 (es)
AU (1) AU2014339136C1 (es)
BR (1) BR112016008161B1 (es)
CA (3) CA3115570C (es)
CY (1) CY1123811T1 (es)
DK (3) DK3293176T3 (es)
ES (3) ES2980505T3 (es)
FI (1) FI3587400T3 (es)
HR (3) HRP20240783T1 (es)
HU (3) HUE046637T2 (es)
IL (4) IL285528B2 (es)
LT (2) LT3293176T (es)
MX (4) MX389002B (es)
MY (1) MY182559A (es)
PH (3) PH12020500162B1 (es)
PL (3) PL3293176T3 (es)
PT (3) PT3060551T (es)
RS (2) RS65452B1 (es)
RU (1) RU2682660C9 (es)
SG (4) SG10202112587RA (es)
SI (3) SI3060551T1 (es)
TW (3) TWI685486B (es)
UA (2) UA127453C2 (es)
WO (1) WO2015059050A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2600830T1 (en) 2010-08-03 2018-05-31 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising a phosphodiesterase inhibitor
JP6458957B2 (ja) 2013-10-22 2019-01-30 チエシ ファルマスティスィ エス．ピー．エー． Ｐｄｅ４阻害剤の製造方法
EP3487501A1 (en) * 2016-07-20 2019-05-29 Allergan, Inc. Methods, compositions, and compounds for treatment of dermatological and ocular conditions
JP7361584B2 (ja) * 2018-12-19 2023-10-16 高砂香料工業株式会社 アミドの還元によるアミンの製造方法
JP6780763B2 (ja) 2018-12-25 2020-11-04 トヨタ自動車株式会社 内燃機関の制御装置
US11149615B2 (en) 2018-12-25 2021-10-19 Toyota Jidosha Kabushiki Kaisha Control device for internal combustion engine
CN111808029A (zh) * 2020-08-31 2020-10-23 兰晟生物医药(苏州)有限公司 一种pde4抑制剂氯比普兰的制备方法
WO2023117985A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
JP2025514863A (ja) 2022-04-27 2025-05-09 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Ｐｄｅ４阻害剤の新規結晶形態
CN115304542B (zh) * 2022-07-18 2024-02-02 湖南华纳大药厂手性药物有限公司 一种3-羟基吡啶的合成工艺
WO2024027901A1 (en) 2022-08-02 2024-02-08 Chiesi Farmaceutici S.P.A. Predictive biomarker of clinical response to a pde4 inhibitor
WO2024062006A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
CN119947705A (zh) 2022-09-22 2025-05-06 奇斯药制品公司 用于施用磷酸二酯酶-4抑制剂的胶囊吸入器
EP4590273A1 (en) 2022-09-22 2025-07-30 Chiesi Farmaceutici S.p.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
KR20250079386A (ko) 2023-11-27 2025-06-04 국립한국해양대학교산학협력단 복수의 학습모델을 이용한 이미지 기반의 강도 추정 장치 및 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935978A (en) * 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
CA2414049A1 (en) * 2000-03-30 2001-10-11 Chirotech Technology Limited Ruthenium-diphosphine complexes and their use as catalysts
EP1670742A1 (en) * 2003-09-12 2006-06-21 Ranbaxy Laboratories Limited Process for the preparation of roflumilast
ES2577303T3 (es) 2004-04-19 2016-07-14 Krka, Tovarna Zdravil, D.D., Novo Mesto Procedimientos para la preparación de la forma polimórfica I de hidrogenosulfato de clopidogrel
DK1749001T3 (da) * 2004-04-29 2010-06-28 Aventis Pharma Inc 3-piperidinylisochroman-5-ol som dopaminagonister
KR20070079278A (ko) 2006-02-01 2007-08-06 삼성전자주식회사 수신자 제한 시스템을 이용하는 디지털 멀티미디어시스템에서 수신기의 채널 전환 시간 단축 장치 및 방법
DE602007012105D1 (de) * 2006-07-14 2011-03-03 Chiesi Farma Spa Derivate von 1-phenyl-2-pyridinylalkylenalkohole als phosphodiesteraseinhibitoren
HRP20110464T1 (hr) * 2006-12-22 2011-07-31 Leo Pharma A/S Supstituirani acetofenoni korisni kao inhibitori pde4
EP2022783A1 (en) * 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
US20100015430A1 (en) 2008-07-16 2010-01-21 Outlast Technologies, Inc. Heat Regulating Article With Moisture Enhanced Temperature Control
EP2216327A1 (en) * 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
EP2580195B1 (en) 2010-06-14 2014-12-03 Chiesi Farmaceutici S.p.A. Crystal form of glycopyrronium chloride
CA2807406C (en) * 2010-08-03 2018-12-11 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
SI2600830T1 (en) * 2010-08-03 2018-05-31 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising a phosphodiesterase inhibitor
SI2643322T1 (en) 2010-11-23 2018-01-31 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
WO2012097479A1 (en) * 2011-01-21 2012-07-26 Abbott Laboratories Bicyclic inhibitors of anaphastic lymphoma kinase
EP2760838B1 (en) * 2011-09-26 2017-05-10 Chiesi Farmaceutici S.p.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
AR089232A1 (es) * 2011-12-16 2014-08-06 Chiesi Farma Spa Potenciacion inducida por inhibidores de pde4 en el tratamiento de la leucemia
AR093796A1 (es) * 2012-12-05 2015-06-24 Chiesi Farm Spa Derivados del alcohol 1-fenil-2-piridinil alquilico como inhibidores de la fosfodiesterasa
CN103304408B (zh) * 2013-06-05 2016-10-05 威海迪素制药有限公司 罗氟司特中间体3-环丙甲氧基-4-二氟甲氧基苯甲酸的制备
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
JP6458957B2 (ja) * 2013-10-22 2019-01-30 チエシ ファルマスティスィ エス．ピー．エー． Ｐｄｅ４阻害剤の製造方法
KR101591785B1 (ko) 2013-12-24 2016-02-04 주식회사 투게더 데이터 입력 장치, 이를 이용한 데이터 전송 시스템 및 방법
MA51413A (fr) * 2017-12-28 2021-04-28 Chiesi Farm Spa Utilisation de dérivés d'alcool alkylique de 1-phényl-2-pyridinyl pour le traitement de la fibrose kystique
WO2023117985A1 (en) * 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity

Also Published As

Publication number Publication date
LT3293176T (lt) 2021-03-25
PT3293176T (pt) 2021-03-03
LT3587400T (lt) 2024-04-25
PH12020500162B1 (en) 2024-06-14
US20210040040A1 (en) 2021-02-11
PH12021550257A1 (en) 2023-01-23
US20240166605A1 (en) 2024-05-23
CA3115570A1 (en) 2015-04-30
PT3587400T (pt) 2024-06-05
CN105658629B (zh) 2019-07-16
BR112016008161B1 (pt) 2022-11-29
AR122182A2 (es) 2022-08-24
US9434691B2 (en) 2016-09-06
SG10201903575UA (en) 2019-05-30
BR112016008161A2 (es) 2017-08-01
EP3798209A1 (en) 2021-03-31
HK1223926A1 (zh) 2017-08-11
PT3060551T (pt) 2019-12-09
TW201605804A (zh) 2016-02-16
IL285532A (en) 2021-09-30
EP3293176A1 (en) 2018-03-14
JP2017505752A (ja) 2017-02-23
IL245220A (en) 2017-06-29
SI3293176T1 (sl) 2021-04-30
PL3293176T3 (pl) 2021-06-28
MX370104B (es) 2019-12-02
RU2016115246A3 (es) 2018-06-27
IL285528A (en) 2021-09-30
FI3587400T3 (fi) 2024-06-20
EP4059921A1 (en) 2022-09-21
TWI685486B (zh) 2020-02-21
TW202021952A (zh) 2020-06-16
SG10201912852YA (en) 2020-02-27
PH12020500162A1 (en) 2021-08-02
US10759761B2 (en) 2020-09-01
HUE067681T2 (hu) 2024-11-28
US20180118686A1 (en) 2018-05-03
CY1123811T1 (el) 2022-05-27
JP2022071008A (ja) 2022-05-13
JP2019038813A (ja) 2019-03-14
MX2019014408A (es) 2020-01-27
IL285532B2 (en) 2024-03-01
UA127453C2 (uk) 2023-08-30
US20160326117A1 (en) 2016-11-10
US11981639B2 (en) 2024-05-14
HRP20210336T1 (hr) 2021-04-16
CA3115587C (en) 2026-01-06
CN114621139A (zh) 2022-06-14
CN120136784A (zh) 2025-06-13
CN105658629A (zh) 2016-06-08
RU2682660C2 (ru) 2019-03-20
PL3587400T3 (pl) 2024-07-01
TWI720803B (zh) 2021-03-01
SG10202112587RA (en) 2021-12-30
RS65452B1 (sr) 2024-05-31
JP7051970B2 (ja) 2022-04-11
EP3587400A2 (en) 2020-01-01
EP3060551B1 (en) 2019-09-18
IL245220A0 (en) 2016-06-30
HRP20192152T1 (hr) 2020-02-21
AR122183A2 (es) 2022-08-24
JP2021011494A (ja) 2021-02-04
US9890122B2 (en) 2018-02-13
KR20210021416A (ko) 2021-02-25
CN120607463A (zh) 2025-09-09
IL285532B1 (en) 2023-11-01
HUE053112T2 (hu) 2021-06-28
KR102240865B9 (ko) 2021-12-13
KR102287598B1 (ko) 2021-08-11
PL3060551T3 (pl) 2020-03-31
HRP20240783T1 (hr) 2024-09-27
IL285528B1 (en) 2025-05-01
IL285528B2 (en) 2025-09-01
HUE046637T2 (hu) 2020-03-30
CA3115587A1 (en) 2015-04-30
PH12016500737B1 (en) 2022-03-23
CA2928242A1 (en) 2015-04-30
JP6458957B2 (ja) 2019-01-30
AR118124A2 (es) 2021-09-22
KR20210021415A (ko) 2021-02-25
US20190345108A1 (en) 2019-11-14
ES2980505T3 (es) 2024-10-01
IL252834B (en) 2021-09-30
TW201904945A (zh) 2019-02-01
AU2014339136C1 (en) 2019-10-31
US10323003B2 (en) 2019-06-18
CA2928242C (en) 2022-03-15
TWI651305B (zh) 2019-02-21
WO2015059050A1 (en) 2015-04-30
US20220348545A1 (en) 2022-11-03
CN114621139B (zh) 2025-06-20
SI3587400T1 (sl) 2024-05-31
DK3293176T3 (da) 2021-02-15
MX389002B (es) 2025-03-20
KR102240865B1 (ko) 2021-04-16
EP3587400A3 (en) 2020-03-25
RU2682660C9 (ru) 2019-06-21
AR098128A1 (es) 2016-05-04
CN110256338A (zh) 2019-09-20
ES2857629T3 (es) 2021-09-29
CA3115570C (en) 2024-01-30
KR20160072127A (ko) 2016-06-22
EP3293176B1 (en) 2020-12-02
SI3060551T1 (sl) 2019-11-29
MY182559A (en) 2021-01-25
MX2016004834A (es) 2016-07-19
RU2016115246A (ru) 2017-11-27
DK3587400T3 (da) 2024-04-02
PH12016500737A1 (en) 2016-05-30
RS61558B1 (sr) 2021-04-29
UA121853C2 (uk) 2020-08-10
JP7534346B2 (ja) 2024-08-14
MX2022000036A (es) 2022-07-19
KR102287596B1 (ko) 2021-08-11
EP3060551A1 (en) 2016-08-31
US11352327B2 (en) 2022-06-07
SG11201603130TA (en) 2016-05-30
EP3587400B1 (en) 2024-03-20
IL252834A0 (en) 2017-08-31
AU2014339136B2 (en) 2018-05-31
JP7345581B2 (ja) 2023-09-15
US20150111931A1 (en) 2015-04-23
DK3060551T3 (da) 2019-10-28
ES2759514T3 (es) 2020-05-11
JP2022068321A (ja) 2022-05-09

Similar Documents

Publication Publication Date Title
MX2022000036A (es) Proceso para la preparacion de un inhibidor de fosfodiesterasa (pde4).
EA201792370A1 (ru) Пиразоло- и триазолопиримидиновые соединения с противовирусной активностью по отношению к rsv
CL2017002650A1 (es) Compuestos novedosos
UY36112A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CU20160065A7 (es) COMPUESTOS DE (PIRROLO[1,2-f][1,2,4]TRIAZINAS, MÉTODOS Y FORMULACIONES FARMACÉUTICAS UTILES PARA TRATAR INFECCIONES POR VIRUS DEL SINCITIO RESPIRATORIO
EA201791274A1 (ru) ЗАМЕЩЕННЫЕ ПИПЕРИДИНОМ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА С ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ РЕПЛИКАЦИИ РЕСПИРАТОРНО-СИНЦИТИАЛЬНОГО ВИРУСА (RSV)
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
BR112014008045A2 (pt) benzilindazóis substituídos para uso como inibidores de bub1 cinase no tratamento de doenças hiperproliferativas
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
BR112015009649A2 (pt) composto de triazolo
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
NI201600014A (es) Compuestos y composiciones como inhibidores de la mek.
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
MX2015010003A (es) Triterpenoides c-19 modificados, con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana (vih).
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
CL2013003056A1 (es) Compuestos derivados de (fenil o piridin)-etinil-(piridin o pirimidin) sustituido; composición farmacéutica que los comprende; proceso de preparación de esto; y su uso en el tratamiento de la esquizofrenia o enfermedades cognitivas.
PH12016502130A1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
CR20170513A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-li-poxigenasa (flap).
NI201500176A (es) Derivados de prodroga de triazolpiridinas sustituidas
BR112015030589A8 (pt) formas polimórficas de fosfato de icotinibe, composição farmacêutica compreendendo as referidas formas e usos das mesmas
AR094866A1 (es) Formas cristalinas de un inhibidor de la prolil hidroxilasa
UY33584A (es) Nuevos compuestos benzamida de inhibidores lrrk2